Australia New Zealand Gynaecological Oncology Group
š¦šŗAustralia
- Country
- š¦šŗAustralia
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.anzgog.org.au
Clinical Trials
4
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)ā¢ Click on a phase to view related trials
Phase 2
4 (100.0%)EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Phase 2
Recruiting
- Conditions
- Ovarian CarcinosarcomaUterine Carcinosarcoma
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-02-04
- Target Recruit Count
- 30
- Registration Number
- NCT05619913
- Locations
- š¦šŗ
Prince of Wales Hospital, Randwick, New South Wales, Australia
š¦šŗRoyal Brisbane and Women's Hospital, Herston, Queensland, Australia
š¦šŗMonash Health, Clayton, Victoria, Australia
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Phase 2
Withdrawn
- Conditions
- Metastatic Cervical Cancer
- Interventions
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
News
No news found